在心力衰竭中,治疗性左向右转移
Francesco Fioretti1,2, Ajith P Nair3, Stefan D Anker4,5
1Baylor Scott & White Research Institute, 3434 Live Oak St., Dallas, TX 75204, USA.
European heart journal
|February 13, 2025
概括
左向右的突变提供了一种新的非药物治疗方法,用于降低心力衰竭患者左心房压升高的情况. 这种疗法旨在改善传统治疗方法不足的症状和结果.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 心脏衰竭研究研究
背景情况:
- 心力衰竭,减少和保留喷射分数,涉及左心房压力升高导致肺堵塞.
- 目前的治疗方法在生活质量和功能能力方面提供了适度的改善,住院率很高.
- 目前正在探索非药理学策略,以减压左心室并增强心力衰竭管理.
研究的目的:
- 审查心力衰竭中左向右的分流疗法的理由和临床证据.
- 综合现有和正在进行的临床试验的发现.
- 确定这个新兴的治疗领域的未来研究方向.
主要方法:
- 对心力衰竭的左向右切换方法的现有文献的综述.
- 从过去和正在进行的临床试验中综合数据.
- 对可能影响分流疗法的有效性因素的分析.
主要成果:
- 左向右的突变显示出降低左心房高血压和改善心力衰竭症状的潜力.
- 疗效可能因患者特定的因素而异,如喷射分数和右心室功能.
- 这种治疗方法仍处于早期阶段,有许多未解答的问题.
结论:
- 左向右的分流疗法是治疗心力衰竭与左心房压升高的有希望的非药物治疗方案.
- 需要进一步的研究来优化患者的选择,并了解这些设备的长期影响.
- 研究患者特征的影响对于个性化治疗策略至关重要.
相关概念视频
Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
374
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311


